Table of Contents Author Guidelines Submit a Manuscript
International Journal of Breast Cancer
Volume 2015, Article ID 536145, 8 pages
http://dx.doi.org/10.1155/2015/536145
Research Article

Assessment of Pathological Response of Breast Carcinoma in Modified Radical Mastectomy Specimens after Neoadjuvant Chemotherapy

1Department of Pathology, Pushpagiri Institute of Medical Sciences and Research Centre, Tiruvalla, Kerala 689101, India
2Department of Pathology, Government Medical College, Thrissur, Kerala 680596, India
3Department of Oncology, Government Medical College, Alappuzha, Kerala 688005, India
4Department of Pathology, Government Medical College, Alappuzha, Kerala 688005, India

Received 30 July 2015; Revised 29 October 2015; Accepted 1 November 2015

Academic Editor: Claudio Luparello

Copyright © 2015 Dhanya Vasudevan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA: A Cancer Journal for Clinicians, vol. 65, no. 2, pp. 87–108, 2015. View at Publisher · View at Google Scholar
  2. Surveillance and epidemiology and end results data, http://seer.cancer.gov/.
  3. Globocon2008 and F. J. Shin, “Cancer incidence & Mortality worldwide,” Sections for cancer information, 2010, http://globocan.iarc.fr/.
  4. Early Breast Carcinoma Trialist Collaborative Group, “Polychemotherapy for early breast cancer: an overview of the randomised trials,” The Lancet, vol. 352, no. 9132, pp. 930–942, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Makris, T. J. Powles, S. E. Ashley et al., “A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer,” Annals of Oncology, vol. 9, no. 11, pp. 1179–1184, 1998. View at Publisher · View at Google Scholar
  6. L. Mauriac, G. MacGrogan, A. Avril et al., “Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up,” Annals of Oncology, vol. 10, no. 1, pp. 47–52, 1999. View at Google Scholar
  7. P. P. Rosen, Rosen's Breast Pathology, chapter 43, Lippincott Williams & Wilkins, Philadelphia, Pa, USA, 1997.
  8. E. Montagna, V. Bagnardi, N. Rotmensz et al., “Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features,” Breast Cancer Research and Treatment, vol. 124, no. 3, pp. 689–699, 2010. View at Publisher · View at Google Scholar
  9. Y. Krishnan, S. Al Awadi, P. S. Sreedharan, S. S. Nair, and S. Thuruthel, “Analysis of neoadjuvant therapies in breast cancer with respect to pathological complete response, disease-free survival and overall survival: 15 years follow-up data from Kuwait,” Asia-Pacific Journal of Clinical Oncology, 2013. View at Publisher · View at Google Scholar
  10. J. Kulka, A. M. Tokés, A. I. Tóth et al., “Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy,” Magyar Onkológia, vol. 53, no. 4, pp. 335–343, 2009. View at Google Scholar
  11. M. Briffod, F. Spyratos, M. Tubiana-Hulin et al., “Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. Cytomorphologic changes, initial tumor ploidy, and tumor regression,” Cancer, vol. 63, no. 4, pp. 631–637, 1989. View at Publisher · View at Google Scholar
  12. L. D. Feldman and G. N. Hortobagyi, “Pathological assessment of responses to induction chemotherapy in breast cancer,” Cancer Research, vol. 46, pp. 2578–2581, 1986. View at Google Scholar
  13. S. J. Vinnicombe, A. D. MacVicar, R. L. Guy et al., “Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation,” Radiology, vol. 198, no. 2, pp. 333–340, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Chevallier, H. Roche, J. P. Olivier et al., “Inflammatory breast cancer, pilot study of intensive induction (FEC-HD) results in a high histological chemotherapy rate,” American Journal of Clinical Oncology, vol. 16, pp. 223–228, 1993. View at Google Scholar
  15. S. Saxena, B. Rekhi, A. Bansal, A. Bagga, Chintamani, and N. S. Murthy, “Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India—a cross-sectional study,” World Journal of Surgical Oncology, vol. 3, article 67, 2005. View at Publisher · View at Google Scholar
  16. S. N. Chin, C. M. A. Green, G. M. Gordon-Strachan, and G. H. F. Wharfe, “Locally advanced breast cancer in Jamaica: prevalence, disease characteristics and response to preoperative therapy,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 7, pp. 3323–3326, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Kaufmann, G. Von Minckwitz, E. P. Mamounas et al., “Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer,” Annals of Surgical Oncology, vol. 19, no. 5, pp. 1508–1516, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. A.-E. Galal, I. Iman, and B. Abdelaziz, “Response of locally advanced breast cancer to primary chemotherapy,” Egyptian Journal of Surgery, vol. 26, no. 3, 2007. View at Google Scholar
  19. I. C. Smith, S. D. Heys, A. W. Hutcheon et al., “Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel,” Journal of Clinical Oncology, vol. 20, no. 6, pp. 1456–1466, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. H. D. Bear, S. Anderson, A. Brown et al., “The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27,” Journal of Clinical Oncology, vol. 21, no. 22, pp. 4165–4174, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. O. M. Fayanju, I. Nwaogu, D. Jeffe, and J. Margenthaler, “Pathological complete response in breast cancer patients following neoadjuvant chemotherapy at a Comprehensive Cancer Center: the natural history of an elusive prognosticator,” Molecular and Clinical Oncology, vol. 3, no. 4, pp. 775–780, 2015. View at Publisher · View at Google Scholar
  22. C. W. Elston and I. O. Ellis, “Classification of malignant breast disease,” in The Breast. Systemic Pathology, C. W. Elston and I. O. Ellis, Eds., pp. 239–247, Churchill Livingstone, Edinburgh, Scotland, 3rd edition, 1998. View at Google Scholar
  23. H. F. Frierson Jr. and R. E. Fechner, “Histologic grade of locally advanced infiltrating ductal carcinoma after treatment with induction chemotherapy,” American Journal of Clinical Pathology, vol. 102, no. 2, pp. 154–157, 1994. View at Google Scholar · View at Scopus
  24. L. A. Newman, H. M. Kuerer, T. L. Smith et al., “Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy,” American Journal of Clinical Oncology, vol. 17, no. 2, pp. 460–469, 1999. View at Google Scholar
  25. E. R. Fisher, J. Wang, J. Bryant, B. Fisher, E. Mamounas, and N. Wolmark, “Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-18,” Cancer, vol. 95, no. 4, pp. 681–695, 2002. View at Publisher · View at Google Scholar · View at Scopus